Maarten IJzerman is professor of clinical Epidemiology & HTA and chair of the department Health Technology & Services Research at the University of Twente, the Netherlands. In 2013 and 2014 he has been the acting Scientific Director of MIRA, Institute for Biomedical Technology and Technical Medicine. Maarten received his MSc in 1993 in Biomedical Health Science at the University of Nijmegen and a PhD in Biomedical Engineering at the University of Twente in 1997. Maarten and his team work on methods to evaluate the benefits of diagnostic and imaging technologies and on the application of outcomes research and decision analytic models to predict health economic impact of medical technologies in development. The early assessment research program intends to further enhance the revenues of public and private spending in biomedical research. An important methodological contribution is made in the use of multi-criteria decision models to elicit stakeholder- and patient preferences for health outcomes and technology.
He has more than 130 peer-reviewed articles in the intersection of engineering, medicine and outcomes research. Maarten is a visiting adjunct professor at Case Western Reserve University in Cleveland (USA) and serves on numerous national and international boards and scientific committees. He is a member of the ISPOR board of directors and is a member of the ISPOR Health Science Policy Council. He is chair of the Committee for revising the Dutch Pharmacoeconomic guidelines (ZINL) and co-chair of the ISPOR taskforce Multi-Criteria Decision Analysis (MCDA). He is a member of the ISPOR taskforces on Simulation Modeling and Statistical Analysis of Conjoint studies. Since 2013, he initiated GITHE (Global Initiative for Translational Health Economics). A joint collaboration between the MIRA Research Institute of the University of Twente (the Netherlands), Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute (The Netherlands), the Fred Hutchinson Cancer Research Center in Seattle (USA), the University of York (UK), UMIT in Hall (Austria) and CRP-Santé and EPEMED (both based in Luxembourg). Originating from their research program, Maarten IJzerman initiated the University spin-off company PANAXEA b.v. in 2010.
Early Stage Modelling of the Health Economic Impact of Circulating Tumour Cells in the Management of Cancer Patients
In this presentation, early health economic modelling is introduced to estimate the potential health impact of implementing CTC diagnostic technologies – with a focus on the potential health impact of using CTCtrap in breast and prostate cancer.